Flowserve (NYSE: FLS) reported earnings on Feb. 22. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Flowserve beat slightly on revenue and beat slightly on earnings per share.

Compared to the prior-year quarter, revenue increased and GAAP earnings per share expanded.

Gross margin dropped, operating margin was steady, and net margin was steady.

Revenue details
Flowserve reported revenue of $1.27 billion. The 10 analysts polled by S&P Capital IQ expected a top line of $1.25 billion on the same basis. GAAP reported sales were 11% higher than the prior-year quarter's $1.14 billion.

My

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Non-GAAP EPS came in at $2.35. The seven earnings estimates compiled by S&P Capital IQ forecast $2.31 per share on the same basis. GAAP EPS of $2.24 for Q4 were 13% higher than the prior-year quarter's $1.99 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 33.2%, 90 basis points worse than the prior-year quarter. Operating margin was 14.8%, about the same as the prior-year quarter. Net margin was 9.9%, about the same as the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $1.09 billion. On the bottom line, the average EPS estimate is $1.74.

Next year's average estimate for revenue is $4.79 billion. The average EPS estimate is $8.74.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 842 members out of 863 rating the stock outperform, and 21 members rating it underperform. Among 238 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 236 give Flowserve a green thumbs-up, and two give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Flowserve is buy, with an average price target of $126.00.